x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:05:00

Hepatic Encephalopathy: More Common Than You Think

CME/CE ·

2025/12/11

Faculty: Arun B. Jesudian, MD This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and

en

00:14:30

A Clear Horizon in Plaque Psoriasis: An Update on...

CME/CE ·

2025/11/26

Faculty: Linda Stein Gold, MD Faculty: April W. Armstrong, MD, MPH Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of

en

00:16:30

Advancing gMG Clinical Decisions: Diagnosing Early,...

CME/CE ·

2025/11/13

Faculty: Christyn Edmundson, MD Faculty: Neelam Goyal, MD This case-based discussion follows Maria, a 38-year-old teacher presenting with fluctuating ptosis, diplopia, and fatigue—classic but easily overlooked signs of generalized myasthenia gravis (gMG). Drs. Goyal and Edmundson review diagnostic strategies for gMG, particularly in seronegative or ocular presentations, and examine FcRn antagonists (efgartigimod, rozanolixizumab, and nipocalimab), using clinical trial data to guide

en

00:00:00

Updates in Major Depressive Disorder with Insomnia

CME/CE ·

2025/11/07

Faculty: Michael E. Thase, MD Faculty: Andrew Krystal, MD Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major

en

00:17:30

Case-Based Approach: Optimizing...

CME/CE ·

2025/10/31

Faculty: Rajiv Agarwal, MBBS, MD, FASN, BRCU Faculty: Prof. Dr. Francesc Xavier Cos Claramunt This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence from the CONFIDENCE and other trials, the discussion highlights the benefits and safety of early

en

00:14:15

Are All VMAT2s The Same? Data Driven Treatment...

CME/CE ·

2025/10/30

Faculty: Christoph U. Correll, MD Faculty: Jonathan M. Meyer Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

en

00:32:30

Mechanism-Driven gMG Therapy: FcRn Antagonists and...

CME/CE ·

2025/10/29

Faculty: Neelam Goyal, MD Faculty: Christyn Edmundson, MD This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY

en

00:42:30

Primary Biliary Cholangitis: Shining Light on an...

CME/CE ·

2025/10/22

Faculty: Gideon Hirschfield, MB, BChir, PhD Faculty: Marlyn Mayo, MD This WHAV 2025 session examines primary biliary cholangitis (PBC), a chronic autoimmune liver disease that predominantly affects women and often goes unrecognized. Tailored for clinicians who play a key role in identifying symptoms and initiating referrals, the session outlines diagnostic criteria—including AMA positivity and elevated ALP—and clarifies when specialist evaluation is warranted. Treatment strategies

en

00:00:00

APOL1 Screening and Early Detection: Patient and...

CME/CE ·

2025/10/21

Faculty: Kirk Campbell, MD Guest: Joshua Albright Guest: Titilayo Ilori, MBBS Host: Kirk Campbell, University of PennsylvaniaGuests: Joshua Albright, Kidney Health Advocate & Titilayo Ilori, Boston UniversityJoin our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Titilayo Ilori (Boston University) and patient advocate Joshua Albright about APOL1 screening and early detection.This episode addresses the low public awareness of APOL1-mediated kidney

en

00:00:00

Burden and pathophysiology of APOL1 kidney disease

CME/CE ·

2025/10/21

Faculty: Kirk Campbell, MD Faculty: Bessie Young, MPH, MD Welcome to KDIGO Conversations in Nephrology: Burden and Pathophysiology of APOL1 Kidney Disease! Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Bessie Young (University of Washington) about the discovery, impact, and future of APOL1 kidney disease. This episode explores the significant burden of kidney disease driven by APOL1 gene variants in individuals with African ancestry. You’ll

en

00:00:00

PI3K Pathway Inhibitors: Safety and Tolerability...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Case in Point: Applying PI3K Combinations in Early...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

The Future of PI3K Inhibition in HR+/HER2- Breast Cancer

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Double Take: Pivotal Data Evaluating PI3K...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Understanding Endocrine Resistance in HR+/HER2- mBC

CME/CE ·

2025/10/07

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and

en

00:00:00

Triple Threat: Key Data on Simultaneous Estrogen,...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:00:00

Comprehensive Biomarker Testing in mBC Informs...

CME/CE ·

2025/10/07

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately

en

00:32:15

New Insights in the Management of HCM: Exploring the...

CME/CE ·

2025/10/02

Faculty: Milind Y. Desai, MD, MBA Faculty: Iacopo Olivotto, MD Faculty: Elena Arbelo, MD, PhD This expert-led program delves into the evolving clinical management of obstructive hypertrophic cardiomyopathy (HCM), emphasizing real-world decision-making across diverse patient profiles. Through dynamic case studies—from young patients with unexplained syncope to older adults at a procedural crossroads—faculty explore how to tailor care using guideline-driven tools and therapeutic

en

00:34:00

Crossing Boundaries: CETP Inhibitors and the Next...

CME/CE ·

2025/10/02

Faculty: Prof. Ulrich Laufs Faculty: Pam R. Taub, MD, FACC, FASPC Faculty: Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma Faculty: Christie Ballantyne, MD Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in

en

277 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事